Novel Corrosion Inhibitor Shows Promise for Blood Research

Researchers at Southwest Petroleum University have developed an imidazo-pyrimidine derivative (IMPY) that shows significant promise as a corrosion inhibitor for blood research. The study, published in the Journal of the Taiwan Institute of Chemical Engineers, found that IMPY exhibits a high inhibitory performance of 98.22% at a dose of 75 mg/L, making it an effective solution for mitigating corrosion in steel exposed to sour gas.

Key Takeaways:

• The researchers synthesized IMPY, a highly degradable and excellent inhibitor for sour corrosion, which significantly decreased the rate of corrosion.
• The study demonstrated that IMPY has impeding properties, and its atomic core relationship was discovered through theoretical assessments.
• Docking research revealed that IMPY has inhibiting capability towards proteins such as COVID-19, NADPH oxidase, xanthine oxidase, and Acidithiobacillus ferrooxidans (1H10).
• The relative binding strengths indicate that IMPY has better xanthine oxidase inhibiting action, suggesting its potential use in biomedicine.
• The research also suggests that IMPY has multifaceted qualities, establishing its status as a safe corrosion suppressor for P110 steel.

Statistics:

• 98.22% inhibitory performance of IMPY at a dose of 75 mg/L.
• 173, the issue number of the Journal of the Taiwan Institute of Chemical Engineers where the study was published.
• 2025, the year in which the study was conducted and published.

Sources:

• Understanding the Adsorption of Imidazo-pyrimidine Derivative Corrosion Inhibitor At the P110 Steel/co2+h2s Saturated Simulated Formation Water Interface: Experimental and Theoretical Elucidation. Journal of the Taiwan Institute of Chemical Engineers, 2025; Volume 173.
• Elsevier - www.elsevier.com
• Journal of the Taiwan Institute of Chemical Engineers - www.journals.elsevier.com/journal-of-the-taiwan-institute-of-chemical-engineers/